Ligand Pharmaceuticals Incorporated (LGND) Shareholder Knott David M Decreased Its Stake by $4.78 Million as Shares Rose

May 17, 2018 - By Jack Shaw

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Corporate LogoDuring Q4 2017 the big money sentiment decreased to 1.25. That’s change of 0.44, from 2017Q3’s 1.69. 21 investors sold all, 86 reduced holdings as LGND ratio turned negative. 103 grew holdings while 31 funds acquired holdings. Funds hold 22.68 million shares thus 0.37% less from 2017Q3’s 22.76 million shares. Moreover, Kopp Advsr Ltd has 3.02% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 22,026 shs. First Republic Management Inc invested in 0.01% or 5,756 shs. Putnam Limited Com holds 0.01% or 19,627 shs in its capital. Price T Rowe Inc Md accumulated 0.01% or 258,134 shs. 47,662 were accumulated by Matarin Capital Mgmt Ltd Co. Nj State Employees Deferred Compensation Plan has 6,000 shs for 0.14% of their capital. Guggenheim Cap Llc owns 37,728 shs. Prudential Fincl reported 78,885 shs stake. Moreover, Woodstock has 1.75% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Redwood Invests Limited Liability Corporation reported 0.87% stake. Summit Creek Advsrs Ltd Limited Liability Company stated it has 42,577 shs or 1.09% of all its holdings. Cornerstone Cap Inc reported 1.77% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 16,502 were accumulated by Martingale Asset L P. Shelton accumulated 1,704 shs. Goldman Sachs Grp Inc reported 221,743 shs.

LGND had 14 sales and 0 buys since December 20, 2017. This’s net activity of $20.00 million. HIGGINS JOHN L sold $4.32M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Friday, January 19. Aryeh Jason sold $529,635 worth of stock or 3,417 shs. Sabba Stephen L sold $112,414 worth of stock or 622 shs. LAMATTINA JOHN L had sold 3,335 shs worth $536,604 on Monday, March 5. FOEHR MATTHEW W had sold 8,881 shs worth $1.49 million. $2.62 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Davis Todd C.

Based on the latest 2017Q4 regulatory filing with the SEC, Knott David M decreased its holdings in Ligand Pharmaceuticals Incorporated (LGND) by 4.4%. 35,156 shares were sold by Knott David M as the company’s stock rose 20.51% while stock markets declined. At the end of 2017Q4, the institutional investor held 762,944 shares of the major pharmaceuticals company, valued at $104.47 million, down from 798,100 at the end of the previous reported quarter. $4.12B is Ligand Pharmaceuticals Incorporated’s market cap. Ticker’s shares touched $193.19 during the last trading session after 4.22% change.Ligand Pharmaceuticals Incorporated has 590,205 shares volume, 83.03% up from normal. LGND is uptrending and has moved 53.11% since May 17, 2017. LGND outperformed the S&P500 by 41.56%.

Knott David M has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

On August, 6 WallStreet anticipated Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s earnings release, as reported by Faxor. This year’s earnings per share analyst estimate is anticipated to be $0.82. That is 51.85 % up compareed to $0.54 earnings per share for last year. This could be $17.47 million profit for LGND assuming the current $0.82 earnings per share will become reality. Analysts at Wall Street see Ligand Pharmaceuticals Incorporated’s -40.58 % negative EPS growth compared to $1.38 earnings per share for last quarter.

For more Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news posted recently go to: Benzinga.com, Streetinsider.com, Streetinsider.com, Streetinsider.com or Globenewswire.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” posted on May 16, 2018, “Ligand Pharma (LGND) Proposed Offering of $650M of Convertible Senior Notes” on May 16, 2018, “Lakewood Capital Notes New Longs in DWS Group, Hyundai and WestRock (WRK); New Shorts in Ligand Pharma …” with a publish date: April 25, 2018, “Ligand Pharma (LGND) Tops Q1 EPS by 40c” and the last “New Research Coverage Highlights Assurant, Williams Partners, Atmos Energy, Nationstar Mortgage, Applied …” with publication date: May 15, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

In total 5 analysts cover Ligand Pharmaceuticals (NASDAQ:LGND). “Buy” rating has 4, “Sell” are 1, while 0 are “Hold”. 80% are bullish. With $200.0 highest and $162.0 lowest target Ligand Pharmaceuticals has $163.80 average target or -15.21% below the current ($193.19) price. 7 are the (NASDAQ:LGND)’s analyst reports since November 20, 2017 according to StockzIntelligence Inc. In Thursday, February 22 report Stephens maintained it with “Buy” rating and $162.0 target. In Wednesday, March 7 report Craig Hallum maintained it with “Buy” rating and $200.0 target. On Wednesday, March 7 the stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by H.C. Wainwright. On Monday, February 26 the rating was maintained by Roth Capital with “Buy”. On Wednesday, January 24 the firm has “Buy” rating by H.C. Wainwright given. On Monday, November 20 the firm earned “Sell” rating by Deutsche Bank. The company rating was maintained by Craig Hallum on Thursday, February 22.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: